文献速递系统性红斑狼疮

狼疮肾炎维持免疫抑制治疗撤药(WIN-Lupus):一项多中心随机对照试验结果

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.
PubMed 文献 · Ann Rheum Dis · 2022-06-20

WIN-Lupus 多中心随机对照试验将接受维持免疫抑制治疗2-3年的增殖性狼疮肾炎患者随机分为继续治疗组与撤药组,主要终点24个月增殖性狼疮肾炎复发率在继续组为5/40(12.5%)、撤药组为12/44(27.3%),撤药非劣效性未成立,撤药组严重SLE flare更常见(5/40 vs 14/44,p=0.035),不良事件两组无差异。

要点

  • 维持免疫抑制治疗2-3年后撤药,24个月增殖性狼疮肾炎复发率继续组5/40(12.5%)vs撤药组12/44(27.3%),非劣效性未成立。
  • 严重SLE flare(肾脏或肾外)继续组5/40 vs撤药组14/44(p=0.035),撤药组更常见。
  • 两组不良事件无差异,至复发时间两组无差异。

核心结论

  • 维持免疫抑制治疗2-3年后撤药对肾脏复发的非劣效性未成立,撤药与严重SLE flare风险更高相关。

研究设计与样本

  • WIN-Lupus为研究者发起的多中心随机对照试验,2011年至2016年随机96例(计划200例),继续组48例、撤药组48例。
  • 入组患者为接受硫唑嘌呤或吗啡麦考酚酯维持免疫抑制治疗2-3年并接受羟氯喹的增殖性狼疮肾炎患者,按1:1随机分为继续治疗组与撤药组。
  • 主要终点为24个月时增殖性狼疮肾炎复发率;主要次要终点包括严重SLE flare发生率、无肾脏复发或严重flare生存、不良事件。

主要发现

  • 增殖性狼疮肾炎复发在继续组为5/40(12.5%),撤药组为12/44(27.3%),差值14.8%(95%CI -1.9至31.5)。
  • 严重SLE flare(肾脏或肾外)继续组5/40 vs撤药组14/44(p=0.035),撤药组更常见。
  • 至复发时间两组无差异,不良事件两组无差异。

关键数值与推荐

  • 主要终点24个月增殖性狼疮肾炎复发率:继续组5/40(12.5%)vs撤药组12/44(27.3%),差值14.8%(95%CI -1.9至31.5),非劣效性未成立。
  • 严重SLE flare(肾脏或肾外):继续组5/40 vs撤药组14/44(p=0.035)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 实际随机96例,低于计划的200例。
  • 非劣效性未成立,撤药与严重SLE flare风险更高相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE). Severe (proliferative) forms of LN are treated with induction immunosuppressive therapy (IST), followed by maintenance IST, to target remission and avoid relapses. The optimal duration of maintenance IST is unknown. The WIN-Lupus trial tested whether IST discontinuation after 2‒3 years was non-inferior to IST continuation for two more years in proliferative LN. METHODS: WIN-Lupus was an investigator-initiated multicentre randomised controlled trial. Patients receiving maintenance IST with azathioprine or mycophenolate mofetil for 2-3 years, and hydroxychloroquine, were randomised (1:1) into two groups: (1) IST continuation and (2) IST discontinuation. The primary endpoint was the relapse rate of proliferative LN at 24 months. Main secondary endpoints were the rate of severe SLE flares, survival without renal relapse or severe flare, adverse events. RESULTS: Between 2011 and 2016, 96 patients (out of 200 planned) were randomised in WIN-Lupus: IST continuation group (n=48), IST discontinuation group (n=48). Relapse of proliferative LN occurred in 5/40 (12.5%) patients with IST continuation and in 12/44 (27.3%) patients with IST discontinuation (difference 14.8% (95% CI -1.9 to 31.5)). Non-inferiority was not demonstrated for relapse rate; time to relapse did not differ between the groups. Severe SLE flares (renal or extrarenal) were less frequent in patients with IST continuation (5/40 vs 14/44 patients; p=0.035). Adverse events did not differ between the groups. CONCLUSIONS: Non-inferiority of maintenance IST discontinuation after 2‒3 years was not demonstrated for renal relapse. IST discontinuation was associated with a higher risk of severe SLE flares. TRIAL REGISTRATION NUMBER: NCT01284725.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022. PMID: 35725295. doi:10.1136/annrheumdis-2022-222435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。